Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 8 Ovarian Neoplasms 7 Fallopian Tube Neoplasms 4 Recurrence 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Neoplasms 2 Breast Neoplasms 2 Phase IB 1 Multiple Myeloma 1 Lung Neoplasms 1 Endometrial Hyperplasia 1 Colonic Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

Megestrol Acetate 7 Medroxyprogesterone Acetate 4 Progestins 3 Metformin 3 Tirzepatide 2 Progesterone 2 Letrozole 2 Hysteroscopy 2 Blood Specimen Collection 2 Biopsy 2 Atorvastatin 2 semaglutide 1 ricin A-GnRH conjugate 1 exemestane 1 estradiol, norethindrone drug combination 1 Tamoxifen 1 Surveys and Questionnaires 1 Sampling Studies 1 Rosuvastatin Calcium 1 Restraint, Physical 1 Resistance Training 1 Pterocarpus marsupium 1 Pharmacogenomic Variants 1 Observation 1 Nutrition Assessment 1 Magnetic Resonance Spectroscopy 1 Levonorgestrel 1 LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1 Intrauterine Devices 1 Immunohistochemistry 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Endometrial Hyperplasia × Everolimus × Gynecologic × Clear all

NCT02397083 2026-02-13

LEVER

M.D. Anderson Cancer Center

Phase 2 Active not recruiting

Endometrial Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡